Product Description
Acipimox is a niacin derivative and nicotinic acid analog with activity as a hypolipidemic agent. Acipimox has special application for the treatment of hyperlipidemia in non-insulin-dependent diabetic patients.
Mechanisms of Action: triglyceride Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Belgium | Chile | China | Denmark | Egypt | Germany | Hungary | India | Ireland | Italy | Korea | Netherlands | New Zealand | Pakistan | Peru | Portugal | South Africa | Switzerland | Taiwan | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Ministry of Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Type 2 Diabetes
Phase 3: Insulin Resistance|Mitochondrial Myopathies|Type 1 Diabetes|Type 2 Diabetes
Phase 2: Type 2 Diabetes|Obesity, Abdominal|Bulimia Nervosa|Heart Failure, Acute|Insulin Resistance|Heart Failure, Chronic|Hypertriglyceridemia
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| GGD | N/A |
Recruiting |
Prediabetes|Prediabetic State |
2025-07-01 |
|
| CTR20231475 | N/A |
Completed |
Hyperlipoproteinemia Type II|Hypertriglyceridemia|Hyperlipoproteinemia Type IV |
2023-07-15 |
|
| ChiCTR2000040140 | N/A |
Not yet recruiting |
Diabetic Nephropathy |
2022-05-20 |
|
| AIMM: Acipimox in Mitochondrial Myopathy | P3 |
Unknown status |
Mitochondrial Myopathies |
2021-08-04 |